Infliximab as a therapeutic alternative in perianal fistulizing Crohn's disease

Authors

Keywords:

CROHN DISEASE, INFLIXIMAB, RECTAL FISTULA, INFLAMMATORY BOWEL DISEASES, BIOLOGICAL TREATMENT.

Abstract

Introduction: Infliximab is a drug, a monoclonal antibody with a potent anti-inflammatory action. Its mechanism of action decreases the effect of tumor necrosis factor, on the other hand, it induces apoptosis (cell death) of abnormally activated lymphocytes. It is one of the so-called biological treatments, developed for the treatment of various diseases, including Crohn's disease which is characterized by segmental granulomatous inflammation of the intestinal tract and usually affects the skin tissues.

Case report: 42-year-old white race male with a history of treatment since 2006, he underwent different treatments with few results. A new therapeutic behavior is taken in 2018 with the monoclonal antibody Infliximab.

Conclusions: results with the new therapy were satisfactory.

Downloads

Download data is not yet available.

Author Biographies

Damary Rodríguez Gutiérrez, Universidad de Ciencias Médicas, Hospital Universitario Manuel Ascunce Domenech. Servicio de Coloproctología. Camagüey. Cuba.

Médico Especialista de Primer Grado en Coloproctología. Máster en Urgencias Médicas. Instructor

Dayan Cervantes Peláez, Universidad de Ciencias Médicas, Hospital Oncologico Maria Curie. Servicio de Cirugía. Camagüey. Cuba.

Médico Especialista de Primer Grado en Coloproctología. Instructor.

Yosvany Rojas Peláez, Universidad de Ciencias Médicas, Policlínico Docente José Martí Pérez. Servicio de Gastroenterología. Camagüey. Cuba.

Médico Especialista de Primer Grado en Medicina General Integral y Gastroenterología. Instructor.

References

1. Merino-Gallego E, Molina-Villalba C, Martínez-Amate E, Gallego-Rojo FJ. Infecciones oportunistas múltiples relacionadas con infliximab en enfermedad inflamatoria intestinal: ¿suspender o continuar la terapia biológica? RAPD [Internet]. Mar-Abr 2017 [citado 08/05/2019]; 40(2): [aprox. 10p.]. Disponible en: https://www.sapd.es/revista/2017/40/2/06

2. British Society of Gastroenterology. BSG guidance on the use of biosimilar infliximab CT-P13 in inflammatory bowel disease [Internet]. Reino Unido: Created; 2016 [cited 08/05/2019]. Available from: www.bsg.org.uk/images/stories/docs/clinical/guidance/bsg_infliximab_guidance_16.pdf

3. Calleja-Hernández MÁ, Martínez-Sesmero JM, Santiago-Josefa B. Biosimilares de anticuerpos monoclonales en enfermedades inflamatorias y cáncer: situación actual, retos y oportunidades. Farmacia Hospitalaria [Internet]. 2020 [citado 08/05/2019]; 44(3): 100-8. Disponible en: https://revistafarmaciahospitalaria.sefh.es/gdcr/index.php/fh/article/view/11280

4. Zaragoza García F, Villaescusa Castillo L, Pi Corrales G, coordinadores. Libro blanco de los medicamentos biosimilares en España: Innovación y Sostenibilidad [Internet]. Madrid, España: Fundación Gaspar Casa; 2017 [citado 08/05/2019]. Disponible en: http://fgcasal.org/publicaciones/Libro-Blanco-de-los-Medicamentos-Biosimilares-en-Espana-Innovacion-y-Sostenibilidad.pdf

5. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology [Internet]. 2011 May [citado 08/05/2019]; 140(6): 1785-1794. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21530745/

6. Molodecky NA, Soon S, Rabi DM, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology [Internet]. 2012 [citado 08/05/2019]; 142(1):46-54. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22001864/

7. Figueroa C. Epidemiología de la enfermedad inflamatoria intestinal. Rev Méd Clín Las Condes [Internet]. Jul-Ago 2019 [citado 08/05/2019]; 30(4): 257-261. Disponible en:

https://www.sciencedirect.com/science/article/pii/S0716864019300562

8. Hawn TR, Berrington WR, Smith IA, Uematsu S, Akira S, Aderem A, et al. Altered inflammatory responses in TLR5-deficient mice infected with Legionella pneumophila. J Inmunol [Internet]. 2007 Nov 15 [citado 08/05/2019]; 179(10): 6881-6887. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17982089/

9. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn`s disease: tha CHARM trial. Gastroenterology [Internet]. 2007 Jan [citado 08/05/2019]; 132(1): 52-65. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17241859/

10. Hospital Clinic de Barcelona. Células madres para curar las fistulas anales en la enfermedad de Crohn. Barcelona: SINC; 2016.

11. Mauryane Lopes A, Bezerra de Moura LN, Silva Machado R da, Freitas da Silva GR. Quality of life of patients with Crohn's disease. Enferm Global [Internet]. 2017 [citado 12/02/2019]; 47: [aprox. 16p.]. Disponible en: http://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=0&sid=5937da67-c65b-420a-a0e9-fe73f75f558d%40pdc-v-sessmgr06

12. López-Cepeda LD, Hernández-Barrios B, Cortés-Esparza JL, Navarrete-Franco G, Ramos Garibay JA, González-González M. Úlceras genitales y perianales como manifestación de enfermedad de Crohn. Dermatol Rev Mex [Internet]. May-Jun 2018 [citado 12/02/2019]; 62(3): [aprox. 9 p.]. Disponible en: https://www.medigraphic.com/pdfs/derrevmex/rmd-2018/rmd183f.pdf

13. Martín Varas C, Heras M, Saiz A, Coloma R, Calle L, Callejas R, et al. Vasculitis asociada a anticuerpo anticitoplasma de neutrófilo en paciente con enfermedad de Crohn en tratamiento con adalimumab. Nefrología [Internet]. 2017 [citado 12/02/2019]; 37(5): [aprox. 3p.]. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0211-69952017000500560

14. Boyapati RK, Torres J, Palmela C, Parker CE, Silverberg OM, Upadhyaya SD, et al. Retiro del tratamiento biológico o inmunosupresor en pacientes con enfermedad de Crohn inactiva [Internet]. Weinheim, Alemania: Cochrane; 2019 [citado 12/02/2019]. Disponible en: https://www.cochranelibrary.com/es/cdsr/doi/10.1002/14651858.CD012540.pub2/full/es

15. Hillock NT, Heard Sh, Kichenadasse G, Hill CL, Andrews J. infliximab for ipilimumab-induced colitis: A series of 13 patients. Asia-Pac J Clin Oncol [Internet]. 2017 [citado 12/02/2019]; 13(3): [aprox. 15p.]. Disponible en: https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.12651

Downloads

Published

2020-07-30

How to Cite

1.
Rodríguez Gutiérrez D, Cervantes Peláez D, Rojas Peláez Y. Infliximab as a therapeutic alternative in perianal fistulizing Crohn’s disease. Rev Ciencias Médicas [Internet]. 2020 Jul. 30 [cited 2025 Aug. 26];24(4):e4420. Available from: https://revcmpinar.sld.cu/index.php/publicaciones/article/view/4420

Issue

Vol. 24 No. 4 (2020)

Section

CASE REPORTS

License

Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.

Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/